-
Axicabtagene ciloleucel, sold
under the
brand name
Yescarta, is a
medication used for the
treatment for
large B-cell
lymphoma that has
failed conventional...
-
precursor acute lymphoblastic leukemia (B-ALL), and
axicabtagene ciloleucel (
Yescarta),
marketed by Kite
Pharma originally for
diffuse large B-cell lymphoma...
-
adenosine deaminase deficiency (ADA-SCID) 26 May 2016
axicabtagene ciloleucel Yescarta Ex
vitro Kite
pharma large B-cell
lymphoma 18
October 2017 23
August 2018...
- of
Yescarta™, a
revolutionary new
immunotherapy for
adult patients with
diffuse large B cell lymphoma, a form of non-Hodgkin's lymphoma.
Yescarta is a...
- By 2022 this
acquisition had led to two
marketed products for lymphoma:
Yescarta and Tecartus. In November, the
company announced it will
acquire Cell Design...
- (Bayer) Yaz
Ycanth Yellox Yentreve Yervoy (Bristol-Myers Squibb)
Yesafili Yescarta Yocon (Teva Pharmaceuticals)
yohimbine (INN)
Yondelis Yonsa Yorvipath Yselty...
- 18
October 2018.
Retrieved 2019-05-28. "Biogen's Spinraza,
Fosun Kite's
Yescarta and a
controversial Alzheimer's drug: All you need to know
about China's...
- annum. The
acquisition was
completed in
October 2017, when Kite Pharma's
Yescarta became the
first CAR-T
therapy approved by the FDA for the
treatment of...
-
pediatric B-ALL;
second autologous CAR T-cell
therapy axicabtagene ciloleucel (
Yescarta) is approved. 2020 – The
first mRNA
vaccines (BNT162b2, mRNA-1273), are...
- 14
December 2019.
Retrieved 13
December 2019.
After Kymriah (Novartis),
Yescarta (Gilead), and
Luxturna (Spark) were
approved in the U.S. in 2017, they...
